The results of the IMpassion132 trial
Elisa Agostinetto shared on X a paper by Rebecca Dent et al. titled “IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer” in Annals of Oncology.
Authors: R. Dent, F. Andre, A. Goncalves, A. Mani, A. Swat, J. Cortes et al.
“Out in Annals of Oncology the results of the IMpassion132 trial.
In patients with TNBC relapsed <12 months after chemotherapy/surgery for early TNBC, OS was not improved by adding atezolizumab to chemotherapy.”
Source: Elisa Agostinetto/X
Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Trained in Milan, Italy, she currently conducts advanced research at Institut Jules Bordet – Université Libre de Bruxelles in Brussels, Belgium.
Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023